Evidence map›Paper›PMID 37166989›Full record

ArticleThe Journal of clinical investigation2023

SELENOP modifies sporadic colorectal carcinogenesis and WNT signaling activity through LRP5/6 interactions.

Jennifer M Pilat, Rachel E Brown, Zhengyi Chen, Nathaniel J Berle, Adrian P Othon, M Kay Washington, Shruti A Anant, Suguru Kurokawa, Victoria H Ng, Joshua J Thompson and 7 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 5 countries.

Jennifer M PilatProgram in Cancer Biology.
Rachel E BrownProgram in Cancer Biology.
Zhengyi ChenProgram in Chemical and Physical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Nathaniel J BerleDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA.
Adrian P OthonVERTICES Postbaccalaureate Research Education Program and.
M Kay WashingtonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Shruti A AnantVanderbilt University, Nashville, Tennessee, USA.
Suguru KurokawaDepartment of Pharmacy, Osaka Ohtani University, Tondabayashi, Osaka, Japan.
Victoria H NgProgram in Cancer Biology.
Joshua J ThompsonProgram in Cancer Biology.
Justin JacobseDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA.
Jeremy A GoettelProgram in Cancer Biology.
Ethan LeeProgram in Cancer Biology.
Yash A ChoksiProgram in Cancer Biology.
Ken S LauProgram in Chemical and Physical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sarah P ShortProgram in Cancer Biology.
Christopher S WilliamsProgram in Cancer Biology.
Vanderbilt University · USVA Tennessee Valley Healthcare System · USInternational Baccalaureate · CHOsaka Ohtani University · JPUniversity of Iowa · USVanderbilt University Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2019 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Shaping the Microenvironment by DPEP1 Facilitates Adenoma ProgressionU54CA274367 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ken S Lau, Martha J. Shrubsole · 2022 to 2026
$9.7M
Mechanism of Wnt signal transductionR35GM122516 · NIGMS · VANDERBILT UNIVERSITY · PI ETHAN LEE · 2017 to 2026
$5.8M
Tuft cell heterogeneity in function, lineage, and structure in ileal inflammatory diseaseR01DK103831 · NIDDK · VANDERBILT UNIVERSITY · PI LAU, KEN S · 2016 to 2024
$4.4M
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis ColiR01CA244188 · NCI · DARTMOUTH COLLEGE · PI AHMED, YASMATH, LEE, ETHAN · 2020 to 2024
$3.2M
A Cereblon signaling network in Wnt-driven cancersR01CA281002 · NCI · DARTMOUTH COLLEGE · PI Yasmath Ahmed, ETHAN LEE · 2023 to 2026
$2.6M
Selenium in gastrointestinal inflammatory diseasesR01DK099204 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILLIAMS, CHRISTOPHER S. · 2014 to 2018
$1.8M
Vanderbilt Experimental Research Training Inclusion Community Engagement Skills (VERTICES)R25GM134979 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR · 2020 to 2024
$1.2M
Antioxidant regulation of intestinal homeostasis and diseaseK01DK123495 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHORT, SARAH PALMER · 2020 to 2024
$732k
BLRD VA I01 BX001426BLRD VA IK2 BX004648NCI NIH HHS F31 CA232272NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA244188NCI NIH HHS U54 CA274367NIDDK NIH HHS F30 DK111107NIDDK NIH HHS F30 DK120149NIDDK NIH HHS K01 DK123495NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK099204NIDDK NIH HHS R01 DK103831NIDDK NIH HHS R03 DK123489NIDDK NIH HHS U24 DK059637NIGMS NIH HHS R25 GM134979NIGMS NIH HHS R35 GM122516
6 · The paper itself

Abstract

Although selenium deficiency correlates with colorectal cancer (CRC) risk, the roles of the selenium-rich antioxidant selenoprotein P (SELENOP) in CRC remain unclear. In this study, we defined SELENOP's contributions to sporadic CRC. In human single-cell cRNA-Seq (scRNA-Seq) data sets, we discovered that SELENOP expression rose as normal colon stem cells transformed into adenomas that progressed into carcinomas. We next examined the effects of Selenop KO in a mouse adenoma model that involved conditional, intestinal epithelium-specific deletion of the tumor suppressor adenomatous polyposis coli (Apc) and found that Selenop KO decreased colon tumor incidence and size. We mechanistically interrogated SELENOP-driven phenotypes in tumor organoids as well as in CRC and noncancer cell lines. Selenop-KO tumor organoids demonstrated defects in organoid formation and decreases in WNT target gene expression, which could be reversed by SELENOP restoration. Moreover, SELENOP increased canonical WNT signaling activity in noncancer and CRC cell lines. In defining the mechanism of action of SELENOP, we mapped protein-protein interactions between SELENOP and the WNT coreceptors low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6). Last, we confirmed that SELENOP-LRP5/6 interactions contributed to the effects of SELENOP on WNT activity. Overall, our results position SELENOP as a modulator of the WNT signaling pathway in sporadic CRC.

Indexed as

AdenomaColorectal NeoplasmsSeleniumAnimalsCarcinogenesisGene Expression Regulation, NeoplasticHumansLow Density Lipoprotein Receptor-Related Protein-5MiceSelenoprotein PWnt Signaling PathwayLow Density Lipoprotein Receptor-Related Protein-5LRP5 protein, humanSeleniumSelenoprotein PColorectal cancerGastroenterology

Identifiers

PMID37166989
PMCPMC10313376
OpenAlexW4376132984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.